intra-nasal ketorolac

Phase 2Small molecule

UUniversity of Texas Southwestern Medical Center

intra-nasal ketorolac is one of 4 small molecule programs targeting Ketorolac. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

KetorolacRecruiting

KetorolacPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Ketorolac

#DrugCompanyPhaseTrials

Marcaine

IInnocoll

Approved

2 2

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Approved

1 3

Toradol

JJavelin Pharmaceuticals

Phase 3

18 4

intra-nasal ketorolac

UUniversity of Texas Southwestern Medical Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Ketorolac

NCT06158620

Clinical

Trials by Indication[1]

Ketorolac1 trial

Intra-nasal Ketorolac for Acute Ureteral Stent-associated Pain Following Ureteroscopy for Stone Disease

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT06158620·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intra-nasal ketorolac. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intra-nasal ketorolac compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intra-nasal ketorolac. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Texas Southwestern Medical Center

intra-nasal ketorolac

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ketorolac1 trial

References

Drug Info

Quick Facts

Related News